HOME >> MEDICINE >> NEWS
FDA approves ZYFLO CR extended-release tablets for chronic treatment of asthma

Napa, CA (May 31, 2007) Dey, L.P. announced today that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) of its marketing partner, Critical Therapeutics, Inc. (Nasdaq: CRTX), for ZYFLO CR (zileuton) extended-release tablets. ZYFLO CR offers twice-daily, extended-release dosing. Under a co-promotion agreement executed between the two companies in March 2007, DEY will co-market Critical Therapeutics ZYFLO CR.

ZYFLO CR and ZYFLO (zileuton tablets) are the only FDA-approved leukotriene synthesis inhibitors for the prophylaxis and chronic treatment of asthma in adults and children 12 years of age and older. ZYFLO CR and ZYFLO are not indicated for use in the reversal of bronchospasm in acute asthma attacks, but can be continued during acute exacerbations of asthma. Leukotrienes are inflammatory mediators in asthma that can trigger asthma symptoms, including inflammation, swelling, bronchoconstriction and mucus secretion. ZYFLO CR uses SkyePharma PLCs (LSE: SKP) proprietary Geomatrix drug delivery technology, which controls the amount and rate of drug released into the body.

We applaud our marketing partners success in securing FDA approval of the only twice-daily leukotriene synthesis inhibitor for asthma, said Mel Engle, President and CEO of DEY. ZYFLO CR has a unique mechanism of action that, combined with its twice-daily dosing regimen, could fundamentally expand and improve the treatment options available to asthma patients. We are delighted to participate in commercializing Critical Therapeutics ZYFLO CR, which will continue to expand DEYs presence in asthma and respiratory care.

In March 2007, Critical Therapeutics and DEY entered into an agreement for the co-promotion of ZYFLO CR and ZYFLO, the immediate-release formulation of zileuton. DEYs sales force began promoting ZYFLO on April 30, 2007. Upon the launch of ZYFLO CR, the combined sales forces of the two companies will begin prom
'"/>

Contact: Harriet Ullman
harriet.ullman@fkhealth.com
617-761-6776
Feinstein Kean Healthcare
31-May-2007


Page: 1 2

Related medicine news :

1. DFG approves 11 new Collaborative Research Centers
2. FDA approves Dey, L.P.s Perforomist inhalation solution for maintenance treatment of COPD
3. VCR -- FDA approves home discharge for US patients
4. FDA approves prescription Zaditor for over-the-counter relief from itchy eyes
5. FDA approves Vectibix to treat patients with metastatic colorectal cancer
6. 5,000 rare diseases need drugs, but Europe only approves a handful each year
7. FDA approves room temperature storage of ZLB Behrings Helixate FS
8. FDA approves new indication for Topamax as initial monotherapy for adults and children with epilepsy
9. FDA approves first blood test to predict risk for stroke
10. FDA approves Boostrix a new US vaccine for adolescents against pertussis
11. Takeda submits new drug application for extended-release type 2 diabetes medication, ACTOplus met

Post Your Comments:
(Date:5/18/2013)... After working diligently for months and putting ... announced the integration of the fitment specs for the redesigned ... to stun the automobile market with its extraordinary features and ... marked as the latest entry in the size it ... for the year 2013. , Aptly suiting its name, ...
(Date:5/18/2013)... During Better Hearing and Speech Month, parents ... protections they have, including the right to bring a ... treatment or hearing aid device, attorney Ronald E. Johnson ... Association has used the month of May to raise ... as cochlear implants, which can improve the quality of ...
(Date:5/18/2013)... Santa Rosa, CA (PRWEB) May 18, 2013 ... comparisons . The simple to read reviews and comprehensive ... unbiased and impartial home security reviews. 6Webs.com just recently ... security alarm system providers. , Tim Smythe from 6Webs.com ... home security systems due to their ease of use, ...
(Date:5/18/2013)... 18, 2013 The California College of ... At the Ayurvedic Spa , the client receives ... practitioner and lifestyle recommendations and stress management techniques ... life", is the traditional healthcare system of India. It ... harmony is the basis for all optimum health. Ayurveda ...
(Date:5/18/2013)... Dr. Robert Tracey, an area leader in dental laser ... of the root causes of sleep apnea to provide and ... Sleep Month, Dr. Tracey points out estimates revealing that 40 ... sleep apnea is one of the most common of all. ... breathing at different times while sleeping. When this happens, the ...
Breaking Medicine News(10 mins):Health News:Renowned Rim Fitments Provider SizeItUp Launched Database Integrations for the 2012 Hyundai Genesis 2Health News:Schachter, Hendy & Johnson PSC Lawyer Says Cochlear Implant Victims Should Know Their Legal Rights 2Health News:Schachter, Hendy & Johnson PSC Lawyer Says Cochlear Implant Victims Should Know Their Legal Rights 3Health News:Best Wireless Home Security System Companies Released by 6Webs.com 2Health News:Ayurveda Spa Treatments Now Offered at the California College of Ayurveda Panchakarma Center 2Health News:Pomona, NY Dentist, Dr. Robert Tracey of General & Laser Assisted Dentistry (GLAD) Highlights Sleep Apnea Dentistry Services for Better Sleep Month 2Health News:Pomona, NY Dentist, Dr. Robert Tracey of General & Laser Assisted Dentistry (GLAD) Highlights Sleep Apnea Dentistry Services for Better Sleep Month 3
(Date:5/17/2013)... JERUSALEM , May 17, 2013 ... a developer of oral drug delivery systems, announced today ... has cleared the Company,s Investigational New Drug application(IND) for ... very pleased to have the FDA clearance to proceed," ... Oramed. "The upcoming trial is a major milestone for ...
(Date:5/17/2013)... Mass. , May 17, 2013  Boston Scientific ... participate at the annual EuroPCR Scientific Program May 21-24 ... are pleased to present a particularly rich and diversified ... Keith Dawkins , M.D., global chief medical ... trials will be presented, including the NG PROMUS trial, ...
(Date:5/16/2013)... Ill. and MECHELEN, Belgium ... GLPG) and AbbVie (NYSE: ABBV ) announced ... to include Crohn,s disease.  Galapagos will fund and complete ... designed to facilitate rapid progression into Phase 3.  Upon ... AbbVie will pay Galapagos $50 million.  The terms of ...
Breaking Medicine Technology:Oramed Receives FDA Clearance to Initiate Oral Insulin Trials in the U.S. 2Oramed Receives FDA Clearance to Initiate Oral Insulin Trials in the U.S. 3Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 2Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 3Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 4Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 5Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 6Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 7Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 8AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 2AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 3AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 4AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 5AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 6
Cached News: